Induced Pluripotent Stem Cells (iPSCs) are a type of stem cells reprogrammed from a multitude of somatic cells into an embryonic like pluripotent state. They have large self-renewal capability and can differentiate into any cell type from all three germ layers [1, 2]. Due to their high differentiation potential, iPSCs emerge as a promising cell model to promote cell differentiation for the regeneration studies. Importantly, iPSCs reprogrammed from rare disease carriers can be subsequently expanded and differentiated indefinitely, allowing for genetically pertinent disease-specific iPSC model for research . iPS cells, thus, are a unique model for studying a variety of processes that occur in the early development of mammals and are a promising tool in cell therapy of human diseases .
iXCells Biotechnologies is proud to offer human iPSCs derived from normal and patient somatic cells (dermal fibroblasts, adipose-derived stem cells, peripheral blood mononuclear cells) with different race, gender, and age options to choose from. The pertinent donor information is available on the CoA or upon request (email@example.com).
These iPSCs are established from a single clone and expanded in feeder-free conditions. iXCell’s iPSCs demonstrate hESC morphology, express pluripotency markers, have normal karyotype, and are integration free. They are negative for mycoplasma, bacteria, yeast, fungi, HIV-1, HBV and HCV.
Figure 1. iXCells human iPS cells are characterized by immunostaining with Oct4, Nanog, TRA-1-60-R, TRA-1-81(Green).
In addition, patient-derived iPS cell lines are also available as separate product. The currently available disease specific iPS cell lines are derived from patients with Type 2 Diabetes (T2D), Alzheimers’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS). More disease-specific iPS lines are under development. We also provide custom iPSC generation and iPSC differentiation services to meet your needs.
|Tissue Origin||Human iPS Cells derived from dermal fibroblasts, adipose-derived stem cells, or peripheral blood mononuclear cells|
|Package Size||~0.5-1.0 million cells/vial|
|Media & Reagents||Human iPSC Feeder-Free Growth Medium (Cat# MD-0019)|
 Medvedev, S. P., Shevchenko, A. I., & Zakian, S. M. (2010). Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine. Acta naturae, 2(2), 18–28.
 Ghaedi, M., & Niklason, L. E. (2019). Human Pluripotent Stem Cells (iPSC) Generation, Culture, and Differentiation to Lung Progenitor Cells. Methods in molecular biology (Clifton, N.J.), 1576, 55–92.
 Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., Shibata, T., Kunisada, T., Takahashi, M., Takahashi, J., Saji, H., & Yamanaka, S. (2011). A more efficient method to generate integration-free human iPS cells. Nature methods, 8(5), 409–412
 Ebert, A. D., Liang, P., & Wu, J. C. (2012). Induced pluripotent stem cells as a disease modeling and drug screening platform. Journal of cardiovascular pharmacology, 60(4), 408–416.